Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 August 2022 | Story Andre Damons | Photo Supplied
Prof Motlalepula Matsabisa, Director of the University of the Free State (UFS) Department of Pharmacology, will jet off to Lomé, Togo, later this month, where he will share his knowledge and expertise on the production of herbal medicines at a special event of the World Health Organisation (WHO) Health Ministers Regional Committee for Africa.

Prof Motlalepula Matsabisa, Director of the University of the Free State (UFS) Department of Pharmacology, will share his knowledge and expertise on the production of herbal medicines at a special event of the World Health Organisation (WHO) Health Ministers Regional Committee for Africa taking place in Lomé, Togo.

This meeting, with the theme Building Back Better: Rethinking and rebuilding resilient health systems in Africa to achieve UHC and health security, is the 72nd session of the WHO Regional Committee for Africa and will take place between 22 and 26 August 2022. The session will be attended by African health ministers as well as the WHO Director-General, Dr Tedros Adhanom Ghebreyesus, WHO Afro Regional Director, Dr Matshidiso Moeti, and our own Minister of Health, Dr Joe Phaahla, among the key attendees.

Prof Matsabisa will give a presentation on fast-tracking research and development and local production of herbal medicines during the second session, with the theme: Lessons to guide strengthening of health product manufacturing in Africa. He will address the meeting as Chairperson of the Regional Advisory Committee on Traditional Medicine for COVID-19 response (REACT).

Event will launch a consultative process of learning

According to documents about the event, the purpose of the meeting is for the WHO Africa Regional Office (AFRO) to seek to collectively develop a roadmap for building resilient health systems. This comes through integrated efforts that coordinated actions across all clusters and teams in the WHO’s regional and country offices, as well as with national, regional, and global partners supporting African countries as they ramp up efforts to recover from the pandemic-induced disruption and build back better towards achieving universal health coverage (UHC) and being prepared for future health emergencies.

This event will launch a consultative process to learn from the lessons and experiences of countries and partners regarding the implementation and identifying successful health system strategies, and to obtain insights from leaders in the region to guide the next steps. The outcomes of the discussions will be used to inform an urgent common approach to building resilient health systems to achieve health security and UHC in Africa.

Prof Matsabisa says he is delighted to be given the opportunity as Chair of REACT to influence the ministers of health on the continent, as well as other key influential persons, to look favourably at inward investing in the development of local therapeutics, including those from natural products. This would not only address health, but broadly cover local industrial development of the herbal industry, job creation, and wealth generation based on our natural resources.  
“I believe it is time that we move away from thinking of procuring products and services and also looking for aid, but to wake up and stand up to do things for ourselves. Vaccine nationalisations have taught us a bitter lesson that we don’t want to repeat.”  

“I wish to relay that the WHO missions I undertook to the many African countries to determine the capabilities for product manufacturing, clinical trials, and research and development, have indicated that Africa has the manpower, the science, technologies, as well as infrastructure capabilities for the local manufacturing of pharmaceutical therapeutics,” says Prof Matsabisa. 

His presentation will be about the readiness of Africa to develop therapeutics for priority diseases based on herbal-based natural products, as well as our readiness – as the continent – to act should we be faced with another pandemic.

COVID-19 did well to prepare the continent for the next major health emergency

Prof Matsabisa will be one of the six panellists for this ministerial session (Session 2: Lessons to guide strengthening of health-product manufacturing in Africa), moderated by Ms Redi Tlhabi. The other panellists will be Hon. Prof Abderrahmane Benbouzid, Minister of Health, Population and Hospital Reform in Algeria; Hon. Dr Joe Phaahla, Minister of Health, South Africa; Dr Ngozi Okonjo-Iweala, Director General, World Trade Organisation; HE Amb. Minata Samate, Commissioner for Health, Humanitarian Affairs and Social Development, AU; and Mr Emmanuel Mujuru, Chair, Federation of African Pharmaceutical Manufacturers Associations. The session will also be attended by the WHO Director, Dr Ghebreyesus, the WHO Afro Regional Director, Dr Moeti, as well as the presidents and ministers of Togo and Senegal.

Prof Matsabisa says COVID-19 did well to prepare the continent for the next major health emergency, and Africa would now be better suited to deal with such. The meeting in Lomé will share those lessons, which ones worked, why they worked, and learn from those that did not work.  

“We cannot, again, be caught off guard and found wanting and be at the mercy of the North for donations and continue to talk about procurement. I will present ways to put in place systems to support the local manufacturing of therapeutics with participation through the African regional economic blocks.” 

“I will also ask the ministers to help with three things: first, to ask the ministers and their heads of state and governments to financially support the R&D and local manufacturing of herbal-based therapeutics, as well as support for the clinical research of African traditional medicines. Second, to support the WHO and its partners in the mobilisation of resources for traditional medicines against COVID-19, as well as for other priority diseases. Third will be to inform the ministers that REACT is ready to be the coordinator for the R&D and support for the clinical trials at country level, and to develop a coordinated collaborative approach to the R&D and local manufacturing, including clinical trials.”

News Archive

MBA Programme - Question And Answer Sheet - 27 May 2004
2004-05-27

1. WHAT MUST THE UNIVERSITY OF THE FREE STATE (UFS) DO TO GET FULL ACCREDITATION FOR THE MBA PROGRAMMES?

According to the Council on Higher Education’s (CHE) evaluation, the three MBA programmes of the UFS clearly and significantly contribute to students’ knowledge and skills, are relevant for the workplace, are appropriately resourced and have an appropriate internal and external programme environment. These programmes are the MBA General, the MBA in Health Care Management and the MBA in Entrepreneurship.

What the Council on Higher Education did find, was a few technical and administrative issues that need to be addressed.

This is why the three MBA programmes of the UFS received conditional accreditation – which in itself is a major achievement for the UFS’s School of Management, which was only four years old at the time of the evaluation.

The following breakdown gives one a sense of the mostly administrative nature of the conditions that have to be met before full accreditation is granted by the CHE:

a. A formal forum of stakeholders: The UFS is required to establish a more structured, inclusive process of review of its MBA programmes. This is an administrative formality already in process.

b. A work allocation model: According to the CHE this is required to regulate the workload of the teaching staff, particularly as student numbers grow, rather than via standard management processes as currently done.

c. Contractual agreements with part-time staff: The UFS is required to enter into formal agreements with part-time and contractual staff as all agreements are currently done on an informal and claim-basis. This is an administrative formality already in process.

d. A formal curriculum committee: According to the CHE, the School of Management had realised the need for a structure – other than the current Faculty Board - where all MBA lecturers can deliberate on the MBA programmes, and serve as a channel for faculty input, consultation and decision-making.

e. A system of external moderators: This need was already identified by the UFS and the system is to be implemented as early as July 2004.

f. A compulsory research component: The UFS is required to introduce a research component which will include the development of research skills for the business environment. The UFS management identified this need and has approved such a component - it is to take effect from January 2005. This is an insufficient element lacking in virtually all MBA programmes in South Africa.

g. Support programmes for learners having problems with numeracy: The UFS identified this as a need for academic support among some learners and has already developed such a programme which will be implemented from January 2005.

The majority of these conditions have been satisfied already and few remaining steps will take effect soon. It is for this reason that the UFS is confident that its three MBA programmes will soon receive full accreditation.

2. WHAT ACCREDITATION DOES THE UFS HAVE FOR ITS MBA PROGRAMME?

The UFS’s School of Management received conditional accreditation for its three MBA programmes.

Two levels of accreditation are awarded to tertiary institutions for their MBA programmes, namely full accreditation and conditional accreditation. When a programme does not comply with the minimum requirements regarding a small number of criteria, conditional accreditation is given. This can be rectified during the short or medium term.

3. IS THERE ANYTHING WRONG WITH THE ACADEMIC CORE OF THE UFS’s MBA PROGRAMMES?

No. The UFS is proud of its three MBA programmes’ reputation in the market and the positive feedback it receives from graduandi and their employers.

The MBA programmes of the UFS meet most of the minimum requirements of the evaluation process.

In particular, the key element of ‘teaching and learning’, which relates to the curriculum and content of the MBA programmes, is beyond question. In other words, the core of what is being taught in our MBA programmes is sound.

4. IS THE UFS’s MBA A WORTHWHILE QUALIFICATION?

Yes. Earlier this year, the School of Management – young as it is - was rated by employers as the best smaller business school in South Africa. This was based on a survey conducted by the Professional Management Review and reported in the Sunday Times Business Times, of 25 January 2004.

The UFS is committed to maintaining these high standards of quality, not only through compliance with the requirements of the CHE, but also through implementing its own quality assurance measures.

Another way in which we benchmark the quality of our MBA programmes is through the partnerships we have formed with institutions such as the DePaul University in Chicago and Kansas State University, both in the US, as well as the Robert Schuman University in France.

For this reason the UFS appreciates and supports the work of the CHE and welcomes its specific findings regarding the three MBA programmes.

It is understandable that the MBA review has caused some nervousness – not least among current MBA students throughout the country.

However, one principle that the UFS management is committed to is this: preparing all our students for a world of challenge and change. Without any doubt the MBA programme of the UFS is a solid preparation.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept